bs-3320R-Biotin [Conjugated Primary Antibody]
PDGFRA(Tyr849)/PDGFRB(Tyr857) Antibody, Biotin Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: PDGFRA Tyr849 + PDGFRB Tyr857

Modification Site: Tyr857

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5156

Source: KLH conjugated synthetic phosphopeptide derived from human PDGF Receptor alpha around the phosphorylation site of Tyr849 [SN(p-Y)VS]

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

The PDGF Receptor Type A (Alpha platelet-derived growth factor receptor precursor, CD140a antigen), a 170kD protein, binds all three isoforms of PDGF with high affinity whereas the PDGF Receptor Type B, a 190kD protein, appears to bind only the PDGF BB homodimer with high affinity. Both receptors are transmembranous, ligand activated protein tyrosine kinases, which phosphorylate a number of important signal transduction proteins, which are bound with differential affinities via SH2 domains. The response of any given cell to PDGF will depend on the types of receptors displayed on the surface and isoforms of PDGF present in the extracellular environment.

Conjugation: Biotin

Excitation/ Emission: N/A

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)

Predicted Molecular Weight: 117


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog
Cow
Sheep
Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Yang Q et al. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade. Cancer Manag Res. 2020 Jun 24;12:4937-4948.Read more>>
  • Wang Haibo. et al. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR- pathway. BRIT J CANCER. 2024 May;:1-14Read more>>